News

Clinical Reseach of Azithromycin

  • Author:Ray Dean
  • Source:www.oceanchinachem,com
  • Release on :2016-06-02

Azithromycin is an antibiotic belonging to the macrolide, erythromycin and other drugs with the same mechanism. Azithromycin is a very common in clinical use of antibiotics commonly used to treat ear disease, sinusitis, pneumonia, throat infections. Azithromycin is a second-generation macrolide drugs, primarily for the treatment of respiratory and reproductive tract infections. Children and adults to treat respiratory tract infections caused by a variety of pathogens, Chlamydia trachomatis infection.

In clinical trials, the majority of adverse events reported were mild to moderate, and after stopping to resume. Rare reports of angioedema and cholestatic jaundice two potentially serious adverse reactions. During the five-day multi-dose clinical trials, 0.7% of patients (both adult and pediatric patients) due to treatment-related adverse events and discontinued Zithromax (azithromycin) treatment. In an interview three days adults 500 mg / day dose therapy, due to treatment-related adverse events and discontinuation rate of 0.6%. In clinical trials in pediatric patients taking 30 mg / kg of the product (single dose or in divided doses 3 days) due to treatment-related adverse reactions and stop testing ratio of about 1%. Most adverse reactions leading to discontinuation and gastrointestinal-related, such as nausea, vomiting, diarrhea or abdominal pain.

Hubei Ocean Biotech Co., Ltd, China pharmaceutical products and APIs supplier, with credible service and the honest management, we have gained good reputation at domestic and abroad market. The main cause is not only for our honesty and service, but more importantly for our quality insurance about the products we offer. That's why customers choose us, our products are rest assured to buy, it is our honesty and service solved customer’s worries. That’s why we could be able to extend our market and serve more people.